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Abstract 
BACKGROUND & AIMS: Patients with acute liver failure (ALF) have defects in innate 
immune responses to microbes (immuneparesis) and are susceptible to sepsis. Cytotoxic T-
lymphocyte associated protein 4 (CTLA4), which interacts with the membrane receptor B7 
(also called CD80 and CD86), is a negative regulator of T-cell activation. We collected T 
cells from patients with ALF and investigated whether inhibitory signals downregulate 
adaptive immune responses in patients with ALF. METHODS: We collected peripheral 
blood mononuclear cells from patients with ALF and controls from September 2013 through 
September 2015 (45 patients with ALF, 20 patients with acute-on-chronic liver failure, 15 
patients with cirrhosis with no evidence of acute decompensation, 20 patients with septic 
shock but no cirrhosis or liver disease, and 20 healthy individuals). Circulating CD4+T cells 
were isolated and analyzed by flow cytometry. CD4+ T cells were incubated with antigen, or 
agonist to CD3 and dendritic cells, with or without antibody against CTLA4; T-cell 
proliferation and protein expression were quantified. We measured levels of soluble B7 
molecules in supernatants of isolated primary hepatocytes, hepatic sinusoidal endothelial 
cells, and biliary epithelial cells from healthy or diseased liver tissues. We also measured 
levels of soluble B7 serum samples from patients and controls, and mice with 
acetaminophen-induced liver injury using ELISAs. RESULTS: Peripheral blood samples 
from patients with ALF had a higher proportion of CD4+ CTLA4+ T cells than controls; 
patients with infections had the highest proportions. CD4+T cells from patients with ALF had 
a reduced proliferative response to antigen or CD3 stimulation compared to cells from 
controls; incubation of CD4+T cells from patients with ALF with an antibody against CTLA4 
increased their proliferative response to antigen and to CD3 stimulation, to the same levels as 
cells from controls. CD4+ T cells from controls upregulated expression of CTLA4 following 
24–48 hrs culture with sera from patients with ALF; these sera were found to have increased 
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concentrations of soluble B7 compared to sera from controls. Necrotic human primary 
hepatocytes exposed to acetaminophen, but not hepatic sinusoidal endothelial cells and 
biliary epithelial cells from patients with ALF, secreted high levels of soluble B7. Sera from 
mice with acetaminophen-induced liver injury contained high levels of soluble B7 compared 
to sera from mice without liver injury. Plasma exchange reduced circulating levels of soluble 
B7 in patients with ALF and expression of CTLA4 on T cells. Conclusions: Peripheral CD4+ 
T cells from patients with ALF have increased expression of CTLA4 compared to individuals 
without ALF; these cells have a reduced response to antigen and CD3 stimulation. We found 
sera of patients with ALF and from mice with liver injury to have high concentrations of 
soluble B7, which upregulates CTLA4 expression by T cells and reduces their response to 
antigen. Plasma exchange reduces levels of B7 in sera from patients with ALF and might be 
used to restore antimicrobial responses to patients. 
KEY WORDS: immune regulation; liver disease; treatment; infection susceptibility 
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Acute liver failure (ALF) occurs following a severe hepatic insult resulting in a 
rapidly progressive clinical syndrome characterized by jaundice, encephalopathy, 
coagulopathy and multiple organ dysfunction1, 2. Whilst the initiating event in ALF is acute 
hepatocellular death, mortality is attributable to a profound activation of systemic 
inflammatory responses (SIRS) and multiple organ dysfunction1-3. Recent studies identify 
defects in innate immune responses to microbial cues, termed immuneparesis, which cause an 
increased susceptibility to secondary infections, a leading cause of mortality in ALF4-7. 
Following acute tissue injury, intracellular components, defined as damage-associated 
molecular pattern molecules (DAMPS) or alarmins, are released by necrotic and apoptotic 
cells and act as “danger” signal molecules that trigger organ specific and systemic 
inflammatory responses8, 9. Studies identify profound elevations in these danger signals in 
patients with acute hepatic inflammatory disorders which recently have been shown to 
modulate the function of myeloid and possibly lymphoid cells10-12. 
Substantial evidence exists in non-hepatic inflammatory disorders (e.g. severe trauma, 
pancreatitis, septic shock) of suppression in T cell-mediated anti-microbial responses that 
account for the immuneparesis and infectious complications encountered in these patients9, 13. 
The acquired immune dysfunction reported in sepsis includes increased regulatory T cells 
(Tregs) with elevated levels of inhibitory receptor including PD-1 and CTLA413, 14 which 
correlate with reduced IFN-γ production and low T cell proliferative capacity15. In murine 
models of sepsis, CTLA4 was also reported to be elevated on CD4+ and CD8+ T cells16. 
Accordingly, blocking PD-1 and CTLA4-mediated negative regulatory pathways 
demonstrated improved survival in animal models of bacterial and fungal sepsis, increased 
pathogen clearance and reversed T cell dysfunction in patients with sepsis16, 17.  However, it 
remains to be determined whether defects in peripheral adaptive immune responses play a 
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role in the immuneparesis reported in ALF. 
CTLA4 (CD152) is a well characterised negative regulator expressed on T cells that 
binds to the same ligands (CD80 and CD86) as CD28, but with a higher affinity18. Upon T 
cell activation, CTLA4 cycles to the cell surface and exerts its inhibitory effect that results in 
attenuated T cell responses and inhibition of IL-2 secretion, a critical cytokine for T cell 
expansion19, 20. In humans, CTLA4 has been implicated in numerous autoimmune diseases 
such as rheumatoid arthritis and systemic lupus erythematosus (SLE)21, 22. In severe sepsis, 
CTLA4 is upregulated resulting in impairment in T cell activation and antimicrobial 
responses17, 23. CTLA4 was the first immune checkpoint receptor to be clinically targeted and 
several studies have demonstrated that antibody blockade of CTLA4 could result in anti-
tumour immunity24, 25. 
In this study, we sought to assess the immunological competence of CD4+ T cells in patients 
with ALF by examining their phenotype and function. Here, we identify adaptive immune 
dysfunction in CD4+ T cells due to a sustained expression of the negative regulator of T cell 
activation, CTLA4, via mechanisms that involve soluble B7 ligands. The impairment of 
peripheral CD4+ T cells adaptive responses in ALF may further contribute to the 
susceptibility to infections seen in these patients.  
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Methods 
Patients Characteristics  
All patients were consecutively recruited from September 2013 to September 2015. 
Subjects were recruited to the study within 24 hours of admission to the liver intensive 
therapy unit (LITU) or liver wards. Patients were categorised into the following groups: ALF 
(n=45: 35 acetaminophen-induced ALF [AALF] and 10 non-acetaminophen induced 
[NAALF], patients with acute-on-chronic liver failure (ACLF; n=20), chronic Liver Disease 
patients with cirrhosis with no evidence of acute decompensation (CLD; n=15), patients with 
septic shock with no underlying cirrhosis/liver disease (sepsis group; n=20), healthy controls 
(HC; n=20). A subset of ALF patients underwent sequential sampling on day 3 (n=7), day 7 
(n=8) and day 14 (n=5) following admission. In addition, a subset ACLF patients underwent 
sequential sampling on day 3 (n=5), day 7 (n=4) and day 14 (n=5). When plasma exchange 
was instituted in ALF patients recruited, further sampling was performed immediately prior 
to PE (pre-PE, n=7) and within 8hours following completion of plasma exchange (post-PE; 
n=7). All patients who fulfilled criteria for ALF were transferred to LITU based on published 
referral guidelines for both acetaminophen and non-acetaminophen induced ALF26. Patients 
with ACLF fulfilled the established diagnostic criteria developed by the EASL-CLIF 
consortium27. This study was approved by the King’s College Hospital ethics committee 
(12/LO/0167). Informed consent was obtained by the next of kin if patients were not able 
unable to provide consent. 
Phenotyping Using Flow Cytometry  
PBMCs isolated through density-gradient centrifugation were surface stained for 
CD3, CD4, CD8, CD45RA, CD45RO, CCR-7, CTLA4, PD-1, CD25, CD62L, CD28, CD40L 
and CD127. Twelve-color flow cytometric analyses were performed using an LSR Fortessa 
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flow cytometer and data were acquired using BD FACSDiva software (Becton Dickinson 
Ltd, Oxford, UK). 
Antigen Recall Responses and CD4+ T cell proliferation 
Specific CD4+ T-cell antigen-recall responses to a pool of HLA class II-restricted T 
cell epitopes at 10µg/ml (CTL Europe GmbH, Germany) were examined in vitro for T cell 
proliferation using either carboxyfluorescein succinimidyl ester (CFSE) or cell proliferation 
dye eFluor®670 (eBioscience, Hatfield, UK) labelling, in the presence or absence of anti-
CTLA4 blocking antibody (10µg/ml) (eBioscience, Hatfield, UK). All blocking antibodies 
used in this study were referenced neutralizing antibodies from the manufacturers. CD4+ T 
cell proliferation was tested by labelling PBMCs with CFSE prior to being placed in culture 
for 6 days. PBMCs were cultured in RPMI 1640 (Thermo Fisher Scientific, Hemel 
Hempstead, UK) supplemented with 10% human AB serum (PAA laboratories Ltd, UK). 
After stimulation for 6 days at 37°C in 5% CO2, cells were harvested and stained for surface 
markers (CD3, CD4 and CD8). Data were collected using LSR Fortessa (BD) and analyzed 
using FlowLogic (Inivai Technologies Pty Ltd, Victoria, Australia). 
DC-CD4+T cell Co-culture 
Allogeneic DCs were generated as previously described28. They were then co-cultured 
with CD4+ T cells from ALF patients in the presence of anti-CD3 (α-CD3) antibody 
(0.5µg/ml) (eBioscience, Hatfield, UK) at optimal ratio of 1:40 (DC to CD4+ T cells) ratio, 
which was selected following a dose response testing (ranging from a 1:1 to a 1:80 DC to 
CD4+ T cells ratio). Cells were co-cultured for 5 days in the presence or absence of anti-
CTLA4 (α-CTLA4) (10µg/ml). Cell division of CD4+ T cell was measured by the dilution of 
CFSE dye using flow cytometry. 
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Effect of Circulating sB7 on CTLA4 Expression 
CD4+ T cells isolated from HC were cultured in fresh medium for 24 and 48 hours at 
5 × 105 cells per well in the presence of 10% ALF (n= 6) or HC (n=4) sera and screened for 
CTLA4 surface expression using flow cytometry. Supernatant were collected for subsequent 
detection of cytokines. Sera samples from both HC and ALF patients were pre-incubated with 
anti-human CD80 or CD86 neutralizing antibodies (α-CD80 or α-CD86) (R&D Systems, 
Abingdon, UK) for 45min at room temperature before addition to CD4+ T cells isolated from 
healthy donors. Cell culture supernatants were collected for assessing cytokine secretion. 
Cells were harvested for phenotyping. Unless otherwise stated, sB7 molecules refer to sCD80 
and sCD86. 
Primary Human Hepatocytes and Kupffer Cells (KC) 
Cryopreserved hepatocytes (Invivogen Paisley, UK) were cultured for 24 hours in the 
presence or absence of 20mM APAP (Sigma, Dorset, UK). Cells were stained using 
apoptotic/necrotic cell kit (PromoCell GmbH, Heidelberg, Germany). Apoptosis and necrosis 
were detected using Annexin V, Ethidium homodimer III (EthD-III), respectively according 
to the manufacturer’s instructions. KCs (Invivogen Paisley, UK) were stimulated overnight in 
the presence of LPS (100ng/ml). Supernatants from hepatocyte and KC cultures were 
collected for assessment of sB7 molecules. 
Isolation and Culture of Hepatic Sinusoidal Endothelial Cells (HSECs) and Biliary Epithelial 
Cells (BECs) 
HSECs and BECs were isolated according to previously described methods29 
approved by the University of Birmingham ethics committee (06/Q2702/61). HSECs were 
cultured in the presence of sera from ALF (n=6) and HC (n=6) at 25%. Supernatant were then 
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collected and assessed for sB7 molecules. Sera pre-conditioned HSEC were cultured for an 
additional 24 hours in the presence of 10ng/ml recombinant human tumour necrosis factor-α 
(TNF-α) and 10ng/ml interferon-γ (IFNγ) (PeproTech, UK). Supernatants were collected for 
assessment of sB7 molecules. 
Co-culture of Monocytes with Apoptotic Neutrophils 
Neutrophils were isolated by density gradient centrifugation as previously described30. 
Neutrophils were re-suspended (106 cells/ml) in fresh complete medium and incubated for 20 
hours (37 ̊C in 5% CO2) in 24-well plates (Corning, USA). Annexin-V kit (BD Biosciences, 
UK) was used to determine the percentage of apoptotic neutrophils, which was over 65%, as 
previously described30. Next, CD14+ monocytes were re-suspended (0.5×106 cells/ml) and 
co-incubated in 1:2 ratio for 4 hours with apoptotic neutrophils. Supernatants were collected 
in order to measure sB7 levels by ELISA.  
ELISA and MSD Multiplex Cytokine Detection System  
Soluble B7 were assessed in cell culture supernatants, human sera and 
acetaminophen-induced (APAP) liver injury model murine models using ELISA. Cytokines 
were also assessed in cell culture supernatant using ELISA and MSD.  
Statistical Analysis  
Parametric statistical analysis was performed using the Student t test. Non-parametric 
analysis was carried out by using the Mann-Whitney U, Wilcoxon matched-pairs signed rank 
and Kruskal–Wallis tests and data are expressed as median [interquartile range]. For 
correlations of CD4+CTLA4+ T-cell frequency and clinical characteristics as well as 
correlations of sB7 ligands and disease severity indices, Spearman rank correlation 
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coefficients were used. Statistical significance was assumed for P values of less than 0.05. All 
analyses were performed by using Graph Pad prism software. 
Other details and additional experimental procedures are provided in the Supplementary 
Materials 
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Results 
Patient Characteristics 
There was no significant difference in median ages of ALF patients when compared 
to HC, while pathological patients groups were significantly older (Supplementary Table 1). 
ALF patients have significantly higher biochemical and physiological indices of acute liver 
injury (MELD, INR, creatinine, and bilirubin) compared to CLD, ACLF and sepsis patients 
(Supplementary Table 1). The number of circulating lymphocytes was significantly reduced 
in ALF patients when compared to CLD and ALCF patients (Supplementary Table 1) while 
no differences were seen when compared with sepsis patients. Moreover, lymphocyte counts 
in AALF correlated negatively with indices of severity of liver injury (INR: r = -0.285, 
P=.04; AST: r = -0.465, P= .001; SIRS scores: r = -0.391, P= .009; and MELD scores: r = -
0.557, P= .0001). The demographic and key clinical characteristics of patients are 
summarised in supplementary Table 1. Clinical data of ALF patients who underwent PE are 
summarised in supplementary Table 2. 
Increased Frequency of Circulating CD4+ T cells in ALF Patients with a Predominantly 
Naïve Phenotype  
In ALF patients, there is an increase in the proportion of circulating CD4+ T cells 
(median 64.01%,  [56.51-71.61]) when compared to healthy (47.17%, [45.17-58.12]) 
(P=.003) and pathological controls (CLD 65.64%, [51.9-74.07], ACLF 57.30% [46.54-69.56] 
and sepsis patients (70.18%, [58.61-77.11]) (Figure 1A). No significant changes were seen in 
the proportion of circulating CD8+ T cells in ALF when compared to HC and pathological 
control groups (Figure 1A). The distribution of naïve and memory subsets is markedly 
different, highlighted by a diminished proportion of memory population 
(CD4+CD45RO+CD45RA-) and an increased proportion of naïve cells (CD4+CD45RO-
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CD45RA+) in ALF compared with HC subjects (ratio memory to naïve: 0.4513%, [0.3328-
0.7557] versus 0.7825%, [0.5961-1.338], P=.001) (Figure 1B). The reduction in the memory 
population was predominantly in the effector memory T cell (TEM) subset (CD4+CCR7-
CD45RO+) (P=.002) (Figure 1 C). 
Circulating CD4+ T Cells in ALF are Characterized by an Immunosuppressive CTLA4 
Positive Phenotype 
We assessed the surface expression of activation and inhibitory markers of T cell 
function. Compared to ACLF, CLD patients and healthy controls, CTLA4 surface expression 
was markedly elevated in CD4+ T cells from ALF patients on admission to the liver intensive 
care unit (P˂.0001) (Figure 2A&B). The increase in CTLA4 expression is detected in both 
AALF and NAALF patients (1.390% [0.6800-6.418] in AALF and 1.985% [1.020-4.470] in 
NAALF compared to 0.1750% [0.0325-0.6225] in healthy controls). In line with previous 
reports, septic shock patients also showed high levels of CTLA4 expression when compared 
to healthy individuals (Figure 2B). However, levels in septic shock patients were significantly 
lower that detected in ALF patients (P=.001). Analyses of CTLA4 expression in sequentially 
collected ALF samples showed that the proportion of CTLA4 expressing CD4+ T cells 
remained significantly higher than healthy controls throughout the course of admission 
(Figure 2C). At day 3 post-admission, CTLA4 levels of expression peaked, 2.5 fold above 
day 1 levels (P=.02) (Figure 2C).  Detailed immunophenotypic analyses of CD4+ T cells 
revealed no significant differences in the frequencies of cells expressing CD25, PD1, CD40L 
CD28 and CD62L among CD4+ T cells in the studied groups (Supplementary Figure 2).   
Distribution of CTLA4 Expression in Different CD4+ T Cell Subsets 
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We extended the observations reported above and investigated the distribution of 
CTLA4 expression on the CD4+ naïve and memory T cell subsets distinguished based on 
expression of CD25, CD127 and CD45RA markers. The distribution of CTLA4 expression 
differed among ALF CD4+ T cell subsets compared to HC. As illustrated in Figure 2D, 
CTLA4 expression was elevated in all CD4+ T cells, most marked in the memory (CD25-
CD127-CD45RA-) when compared to the naïve (CD25lowCD127+CD45RA+) subset.  In line 
with previously published studies in systemic inflammatory pathologies31, levels were also 
high in the T regulatory subset (CD25+CD127-) (Supplementary Figure 4).  
 CD4+CTLA4+ T Cells Correlate With Disease Severity and Infectious Complications in ALF 
CTLA4 expression by CD4+ T cells was higher in patients who developed culture 
positive infections compared to non-infected patients (P=.04) (Figure 2E). When assessed for 
correlation with their corresponding clinical parameters, patients sampled on day 1 of 
admission who later developed culture-positive infection had elevated frequency of 
CTLA4+CD4+ T cell which correlated positively with MELD score (r=0.675, P=.01) (Figure 
2E) and ammonia (r=0.771, P=.07) (Table 1). Analyses of the distribution of CTLA4 
expression among naïve and memory subsets in patients following admission revealed that 
percentage of memory cells expressing CTLA4 peaked on day 3 following admission (Figure 
2E), particularly within the infected cohort (1.330%, [0.1900-2.470] on day 1 compared to 
9.320%, [0.800-17.84] on day 3) (Supplementary Figure 5).  No differences were noted in the 
distribution of CTLA4 when infected ACLF groups were compared to non-infected ACLF 
(Supplementary Figure 3A&B).   
Defects in CD4+-Mediated T Cell Responses are Restored through Blocking CTLA4 
To investigate whether phenotypic changes reflect a change in the functional capacity 
in CD4+ T cells in ALF, we assessed the proliferative capacity of CD4+ T cells using both 
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antigen-dependent and independent systems. Firstly, in response to MHC-II restricted recall 
antigens, we reveal that T cell proliferation and IL-2 secretion were significantly reduced in 
ALF (P=.008 and P=.02, respectively) when compared to HC (Figure 3 A&B). T cell 
proliferation was reversed following blockade of the CTLA4 pathway (P=.007) (Figure 3C). 
Significant increases in T cell proliferation following CTLA4 pathway blockade in ACLF or 
CLD patient groups was not detected (Figure 3C). IL-2 production was induced following 
CTLA4 blockade in ALF (12.50 pg/ml [9.810-40.25]) (P=.01). IFN-γ levels were also 
restored, but did not reach statistical significance (Supplementary Figure 7A). Furthermore, 
the improvement in proliferative capabilities was most pronounced in memory 
CD4+CD45RO+ subset (Figure 3D). Then, we determined whether CD4+ T cells from ALF 
patients responded to TCR-mediated activation with α-CD3 antibody in the presence of 
allogeneic healthy donor-monocyte-derived DC.  CD4+ T cells isolated from HCs underwent 
more cell divisions in co-culture with allogeneic DC following α-CD3 antibody stimulation 
than the high expressing CTLA4 CD4+ T cells derived from ALF patients (Figure 3E). To 
confirm the suppressive effect of CTLA4 in CD4+ T cells from ALF patients, co-cultures 
were carried out in the presence of anti-CTLA4 antibody. Blocking CTLA4 activity restored 
CD4+ T cell proliferation (P=.03) and IL-2 production (114.8 pg/ml [61.51-172.4] compared 
to 244.1pg/ml [165.9- 294.6] after blocking CTLA4) (P=.04). Analyses of CD4+ T cell 
function following CTLA4 blockade revealed no significant differences in the ACLF and 
CLD patient groups (Figure 3E). 
Soluble Circulating Mediators in ALF Regulate CTLA4 Expression 
In view of the importance of the inflammatory microenvironment in modulating 
immune cell function in ALF4, 6, 7, 32, we investigated the effects of sera, derived from ALF 
patients, on CTLA4 expression in CD4+ T cells from HC. Exposure to sera from ALF patients 
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resulted in up-regulation of CTLA4 expression on CD4+ T cells following 24 and 48 hours in 
culture (P=.01) (Figure 4A). Similar to the effect of sera from ALF patients, we report an 
elevation in CTLA4 expression following exposure to sera from sepsis patients. However, 
these levels were still significantly lower than what we detect following exposure to sera 
derived from ALF patients (Figure 4B). No effect on CTLA4 up-regulation was detected in 
cultures of CD4+ T cells in sera derived from ACLF and CLD patients (Figure 4B).  
In order to provide a mechanistic explanation for the activation of the CTLA4 
pathway in ALF, we sought to investigate the role of circulating soluble B7 molecules 
(sCD80 and sCD86).  Here, we detected a marked elevation in circulating concentrations of 
sCD80 and sCD86 in ALF compared with sera from ACLF, CLD and HCs (Figure 4C-E). 
Similar to the CTLA4 levels, sB7 concentrations peaked at day 3 of admission (P=.03) and 
remained persistently elevated until day 14 (Figure 4D).  
We hypothesised that high levels of circulating sB7 detected in ALF are responsible for the 
activation of the CTLA4 pathway in circulating CD4+ T cells. To test this hypothesis, we 
assessed the effect of neutralising sCD80 and CD86 in ALF sera prior to exposure to CD4+ T 
cells from HCs. As shown in Figure 4F, elevations in CTLA4 expressing CD4+ T cells were 
significantly reduced whilst proliferation and IL-2 secretion were augmented (P=.01 and 
P=.002, respectively) following neutralisation of sCD80 and sCD86 in sera derived from 
ALF patients when compared to  HC (Figure 4F). Similarly, we report an increase in levels of 
IFN-γ, but this did not reach statistical significance (Supplementary Figure 7B) 
sB7 are Secreted by Injured Hepatocytes in ALF 
In order to investigate the source of the increased circulating levels of sB7 molecules 
in the circulation, we assessed the ability of hepatic parenchymal (hepatocytes and biliary 
epithelial cells) and non-parenchymal cells (Kupffer cells, monocytes) to release sB7 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
17 
 
following in vitro and in an in vivo model of APAP-induced acute liver injury. Whilst 
immune cells, HSECs and biliary epithelial cells in ALF did not release increased 
concentrations of sB7, APAP-treated necrotic primary human hepatocytes (Figure 5A) 
released high levels of sB7 (Figure 5B). No detectable levels of sB7 ligands were seen in all 
tested activated and non-activated immune and non-immune cell types. Epithelial cell death 
was further validated by assessing levels of cell death markers (caspase-cleaved [CK-18 
(M30)] and total cytokeratin [CK-18 (M65)] (Figure 5B). In addition to elevated levels of 
sB7, primary human hepatocytes secreted elevated levels of M30 and M65 following APAP-
treatment (Figure 5B). We further assessed sera concentrations of M30 and M65 in ALF 
patients. Levels of M30 and M65 were significantly elevated in ALF patients (Figure 5 C) 
and strongly correlated with release of sCD86 (M30: r = 0.492, P=.01; M65: r = 0.420, P= 
.03).    
Having demonstrated in vitro that APAP-treated hepatocytes represented the main source of 
sB7, we postulated that sB7 are released as early mediators from damaged hepatocytes and 
play a key role in initiating and maintaining elevated CTLA4 expression levels on circulating 
CD4+ T cells. We examined this in vivo using a time course APAP-induced acute liver injury 
murine model33 (Figure 5D). Consistent with the in vitro findings, APAP-injury resulted in 
the release of increased concentrations of sB7, which were detected in the sera as early as 8 
hours post APAP-treatment (initiation phase) (P=.007), remained elevated between 8 and 24 
hours (peak liver injury) and significantly decreased at 48 hours onwards (resolution phase) 
(P=.0.03) to return to baseline levels after 5 days (Figure 5E).  
Plasma Exchange Modulates CTLA4 Activation through Clearance of Circulating sB7 
Molecules in ALF  
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Plasma exchange (PE) has been previously reported to be an important therapeutic 
intervention capable of modulating innate immune responses in ALF but its effects on 
adaptive immunity are not known 12. We assessed the levels of sCD80 and sCD86 and 
showed that these were significantly reduced following PE (Figure 6A). In contrast, no 
reductions in sB7 levels were detected in ALF patients who did not undergo PE (Figure 6B). 
To assess whether these reductions in circulating titres of sB7 molecules attenuate CTLA4 
expression, we performed in vitro cultures quantifying the CTLA4 expression on CD4+ T 
cells following incubation of HC derived CD4+ T cells in sera obtained from ALF patients 
prior (pre-PE) and following (post-PE) plasma exchange. Exposure of D4+ T cell to pre-PE 
sera resulted in a significant increase in CTLA4 levels whereas exposure to post-PE sera did 
not (Figure 6A). These results indicate that PE sera drive a markedly different phenotype of 
the CD4+ T cell population characterised by reduced levels of CTLA4.  
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Discussion 
This study identifies adaptive immune dysfunction, mediated through CTLA4 that is 
triggered by soluble co-stimulatory sB7 molecules released from the acutely inflamed liver in 
patients with ALF.  Here, we identify not only a numerical reduction in circulating 
lymphocytes but also an increased proportion of CD4+ T cells bearing the inhibitory, CTLA4 
positive, phenotype specifically in AALF and NAALF patients and not in other acute and 
chronic hepatic inflammatory diseases. CTLA4 expression was particularly elevated in 
memory CD4+ T cell, an immune cell subset responsible for protective immunity against 
microbial pathogens34. These findings are likely to be of pathogenic significance in ALF 
given that higher level of CTLA4 expressing cells on admission are detected in patients who 
proceed to develop culture positive secondary infections. Therefore, the elevated CTLA4 
levels in the memory CD4+ T cell compartment is likely to reflect an impaired capacity to 
protect against re-infection and a defect in producing robust effector function responses upon 
microbial challenge. The increased proportion of CTLA4 bearing cells in ALF indicates a 
central role for CTLA4 pathway in the predisposition to infection and that blockade of this 
immunosuppressive pathway may be beneficial in restoring anti-microbial responses. We 
reveal that blocking activation of the CTLA4 pathway significantly restores antigen-specific 
responses particularly in the memory CD4+ T cell subset; with similar findings reported in 
CTLA4 expressing memory CD8+ T cells35. It is interesting to note that infected ALF patients 
had persistent elevated CTLA4 expression on CD4+ T cells. In this regard, several 
experimental and clinical studies showed the involvement of CTLA4-mediated negative 
regulation in infections36, 37. CTLA4 was reported to be expressed at higher levels in patients 
with sepsis than in non-sepsis critically ill patients and was associated with impairment in T 
cell responses38, 39. Furthermore, in severe sepsis T cell apoptosis and dysfunction were 
associated with an up-regulation of CTLA4 on CD4+ T cells40, 41. Similarly, increased levels 
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of CTLA4 were implicated in viral infection-associated complications42, 43. Accordingly, in 
murine models of bacterial and fungal sepsis, blocking CTLA4 improved pathogen clearance 
and survival16, 17.  
The immune regulatory functions of the B7/CD28/CTLA4 pathway are well 
recognized in acquired immunodeficiency and autoimmune disorders44, 45. It is known that 
membrane bound CD80 and 86 represent the shared ligands for CD28 and CTLA4, 46. 
However, it has also been shown that soluble forms of B7 molecules represent an alternative 
powerful mechanism by which antigen presenting cells could modulate the signals normally 
generated via membrane bound forms of B7. Experimental studies indicate that recombinant 
soluble B7 molecules represent a putative mechanism for modulating T cell responses 
through either inhibition or enhancement of immune responses47, 48. In this study, we provide 
a novel mechanistic explanation as to the pathogenesis of adaptive immune dysfunction in 
patients with ALF. Here, we report a marked and persistent elevation in circulating titres of 
soluble B7 molecules, in particular sCD86, which strongly correlate with indices of severity 
of acute hepatic injury and more specific markers of hepatocellular death (M30/M65). In 
view of these findings, we hypothesized that the origin and release of these molecules was 
from the acutely injured liver. We screened for sB7 release in parenchymal and non-
parenchymal cells and we identify that the likely origin of sB7 molecules is from hepatocytes 
which have undergone necrotic cell death following APAP administration. This finding is 
corroborated by in vivo data from the murine model of APAP- induced liver injury where 
highest circulating titres of sB7 are detected at peak hepatoxicity. Taken together, we 
highlight a novel role for soluble B7 molecules, released following hepatocyte cell death,  
that negatively regulate the adaptive immune responses through activation of the CTLA4 
pathway. Although our data support that epithelial cell death is responsible for increased 
levels of sB7, in particular sCD86, it cannot be excluded that during ALF, renal replacement 
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therapy (RRT) alone would be a sufficient modality in clearing the sudden increase in 
concentrations of these circulating proteins form the circulation. This is supported by our 
findings where we identify that plasma exchange that does result in significant reductions in 
the concentrations of sCD86 levels in patients with acute liver injury. Further studies are 
required to determine whether this mechanism of adaptive immune dysfunction is common to 
other hepatic and non-hepatic systemic inflammatory pathologies characterised by sudden 
and overwhelming acute tissue injury9.  
  This work has identified a novel therapeutic target to reverse immune dysfunction in 
patients with ALF. CTLA4 inhibitory strategies are established immune checkpoint inhibitors 
in malignant and non-malignant inflammatory pathologies16, 25, 49. However, there would be 
concern regarding the use of this immunotherapeutic strategy in ALF (e.g. ipiluminab) given 
its significant side effect profile (e.g. colitis, dermatitis and autoimmune hepatitis24) and 
potential risk in impairing hepatic regenerative responses.  
Plasma exchange has been recently shown to be of benefit in patients with ALF 
through clearance of damage associated molecular patterns (DAMPs) and other intracellular 
products released from the injured liver12.  Given the fact that soluble B7 molecules, released 
from necrotic hepatocytes, are responsible for activation of the CTLA4 pathway, we 
postulated that plasma exchange would attenuate CTLA4 levels through removal of soluble 
B7 molecules.  Here we demonstrate that plasma exchange significantly reduces circulating 
titres of soluble B7 molecules, in particular sCD86, and CTLA4 expression. This data 
indicate that plasma exchange has beneficial effects in modulating not only innate, but also 
adaptive immune responses and therefore may represent a plausible therapeutic strategy to 
restore adaptive immune responses, reverse immuneparesis whilst the injured liver undergoes 
regeneration in ALF. Future prospective studies are required to address this important 
question. 
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In summary, we show that activation CTLA4 pathway is responsible for adaptive 
immune dysfunction, immuneparesis and infection susceptibility in patients with ALF. 
Furthermore, we highlight the role of soluble B7 molecules, released from acutely injured 
liver, in upregulating this suppressive pathway in circulating CD4+ T cells. Plasma exchange 
may represent a credible immunotherapeutic strategy aimed at restoring adaptive immune 
responses against microbial pathogens by reducing concentrations soluble B7 molecules and 
CTLA4 bearing T cells.   
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Table 1. Clinical and physiological characteristics of culture positive infected and non-
infected AALF patients. 
 
Parameter AALF 
Infected 
AALF 
Non-infected 
Number of 
patients 
11 24 
Age, yr 
  
31.00 
[27.00-49.00] 
36.00 
[27.00-48.00] 
WBC 
(×109/L) 
6.700 
[5.910-8.130] 
8.710 
[5.925-11.61] 
Monocytes 
(×109/L) 
0.2000 
[0.1300-0.2600] 
0.3200 
[0.1250-0.6050] 
  
Lymphocytes 
(×109/L) 
0.5100 
[0.3000-0.7400] 
0.7400 
[0.3200-1.105] 
SIRS SCORE 3.000 
[2.000-4.000] 
3.000 
[2.000-4.000] 
MELD score 39.00 
[37.00-43.00] 
39.00 
[31.00-41.00] 
Bilirubin 
(µmol/L) 
70.00 
[44.00-140.0] 
90.00 
[69.00-162.0] 
INR 4.040 
[2.870-6.250] 
4.480 
[2.480-6.340] 
Creatinine 
(µmol/L) 
259.0 
[90.00-360.0] 
93.00 
[63.00-239.5] 
Urea 
(mmol/L) 
11.30 
[5.700-14.00] 
7.000 
[4.900-8.700] 
AST 
(IU/ml) 
4703* 
[2521-8861] 
1665 
[951.5-3756] 
Ammonia 
(µmol/L) 
87.50 
[54.75-138.5] 
99.00 
[67.50-150.3] 
Encephalopathy 
score 
3.000** 
[3.000-4.000] 
2.000 
[1.000-3.000] 
CTLA4 (%) 3.005** 
[0.8575-6.418] 
1.200 
[0.6750-3.015] 
Outcome
#
 
(number) 
OLT(2) 
Survivors (6) 
Non-survivors (3) 
OLT(8) 
Survivors (16) 
Non-Survivors (0) 
 
Note. Values represent medians [interquartile range]. Abbreviations: SIRS score: Systemic 
Inflammatory Response Syndrome criteria score; MELD: Model for End stage Liver Disease; 
INR: international normalised ratio; AST: aspartate aminotransferase. ALD: acute liver 
disease; OLT: orthotopic liver transplantation; NA: not applicable; ND: Not determined. 
#
outcome at 28 days post admission. *P=0.01 and ** P<0.002, compared to non-infected 
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Figure Legends: 
 
Figure 1. Phenotypic characterisation of T cell subsets in PBMCs of ALF patients. Gating 
strategy to define lymphocyte subsets is described in supplementary materials 
(Supplementary Figure 1). (A) Immunophenotyping of circulating lymphocytes using flow 
cytometry. Data show the percentages of circulating CD3
+
, CD4
+
 and CD8
+
 T cells in ALF 
compared with HC and pathological control groups. (B) Distribution of naïve CD45RO-RA+ 
and memory CD45RO
+
RA
-
 subpopulations within the expanded CD4
+
 T cells population in 
ALF compared with healthy and pathological control groups. Data show ratios of percentage 
of expression. (C) CD4+ T cells were sub grouped into TEM (CD3
+
CD4
+
CD8
-
CCR7
+
CD45RO
-) and T
cm
 (CD3+CD4+CD8-CCR7+CD45RO+) populations. Percentages of 
expression are shown (Healthy controls (HC), n=20; ALF, n=45; CLD; n=15, ACLF, n=20; 
patients with septic shock with no underlying cirrhosis/liver disease (sepsis), n=20).  
Figure 2. Percentages of CTLA4 expressing CD4+ T cells are elevated in ALF patients. (A) 
Representative flow cytometry plots to determine CTLA4 expressing CD4+ T cells in HC 
(left), ALF (middle) and pathological controls (right). (B) Data show that percentages of 
circulating CD4+ T cells expressing CTLA4 are significantly elevated in ALF compared to 
HCs (P˂.0001). (C) CTLA4 levels were determined in sequential samples at day 3 (n=7), 7 
(n=8) and 14 (n=5) following admission and compared to HC levels, represented by the 
dashed line. (D) Left.  Representative plot to define CD3+CD4+ T regs, naïve and memory 
subsets using CD25 and CD127 markers. Right. Distribution of CTLA4 expression in 
different CD4+ T cell subsets, mainly naïve and memory subsets on day 1 of submission 
(n=15). (E) CTLA4 expression was assessed in ALF patients who developed infections 
(n=11) and the ones who did not develop infections (n=23). (E) Distribution of CTLA4+CD4+ 
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among memory and naïve T cell subsets assessed in longitudinal samples on days 1 (n=6), 3 
(n=7), 7 (n=8) and 14 (n=5) following admission. 
Figure 3. Attenuated ALF recall responses to HLA class II-restricted T cell epitopes.  (A) 
PBMCs from HCs (n=5) and ALF (n=5) were labelled with CFSE and stimulated for 6 days 
with HLA class II-restricted T cell peptide pool at 10µg/ml and examined in vitro in the 
presence or absence of α-CTLA4 blocking antibody (10µg/ml). Recall responses induced in 
the CD3+CD8-CD4+ T cell population were assessed and expressed as percentages of 
proliferating cells. Representative flow cytometry histograms of the proliferation responses 
(shown within the marker gate) in HCs (left) and ALF (right) and assessed in the absence (top 
panels) or the presence (bottom panels) of α-CTLA4 AB. (B) The resulting proliferation (B, 
left) and IL2 production (B, right) were determined by flow cytometry and ELISA, 
respectively. (C) Proliferation in CD4+ T cells in ALF (n=8), CLD (n=4), ACLF (n=4) and 
sepsis (n=6) following neutralization of CTLA4. (D) CTLA4 blockade using α-CTLA4 
antibody restored proliferation particularly in the memory subset (n=5). (E) Representative 
flow cytometry histograms of proliferation of isolated CD4+T cells from ALF patients 
labelled with CPD efluor 670 and co-cultured with monocyte-derived healthy donor DCs 
(1:40 DC:CD4+ T cell ratio) in the presence of α–CD3 antibody (left histogram). Data show 
the resulting proliferation at day 5 (right panel) in the presence or absence of α-CTLA4 in 
ALF (n=8), CLD (n=4), ACLF (n=4) and sepsis (n=6).   
Figure 4. Effect of circulating soluble mediators on CTLA4 expression. (A) CTLA4 levels in 
purified CD4+ T conditioned in media supplemented with HC (n=12) or ALF sera (n=14) 
were analysed using flow cytometry following 24 and 48 hr culture. (B) CTL-4 levels in 
purified CD4+ T cells conditioned in media supplemented with sera from ACLF (n=15), CLD 
(6) or sepsis (n=10) sera in comparison to levels induced by culture in the presence of ALF 
and normal sera (C) Detection of levels of soluble costimulatory molecules sCD80 and CD86 
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in sera samples from ALF (n=20) and HC (n=10) by ELISA. (C) sCD80 and sCD86 in 
sequential samples on day 1 (n=12), 3 (n=6), 7 (n=7) and 14 days (n=5) following admission. 
(D) Healthy and ALF sera were preincubated with anti-CD80 or CD86 to block soluble CD80 
or CD86, respectively. Results are representative of 8 independent experiments. (E) 
circulating levels of sCD86 and sCD80 in sera from ALF (n=25), ACLF (n=20), CLD (n=15) 
and sepsis (n=20) patients determined by ELISA (F) Representative histograms gated on 
CD3+ T cells demonstrating proliferation percentages of CFSE-labelled CD4+ T cells 
preconditioned in ALF sera in the absence (top histogram) or presence (bottom histogram) of 
pre-treatment with αCD80 or CD86 blocking antibodies. Proliferation (middle panel) and IL-
2 secretion (right panel) are from 5 independent experiments. 
Figure 5. Human and murine sources of soluble sCD80 and sCD86. (A) Hepatocytes were 
first assessed for apoptosis and necrosis. Apoptotic cells are stained brightly green and 
necrotic brightly red. (B) Primary human hepatocytes were tested for their ability to secrete 
sCD86 hepatocytes following APAP treatment. Supernatants from 24 hour post-APAP-
treated hepatocytes were assessed by ELISA for concentrations of sCD86 (top panel) and for 
soluble cell death markers (M30 and M65) (bottom panel). (C) Circulating levels of M30 (left 
panel) and M65 (right panel) in ALF (n=25), ACLF (n=20), CLD (n=15) and sepsis (n=20) 
patients determined in sera by ELISA (D) Representative H&E stained histology sections of 
liver tissue from murine model of APAP-induced liver injury highlighting different stages in 
the evolution and recovery from APAP-induced liver injury. Liver injury initiation 
(characterized by centrilobular hepatocyte necrosis) (8 hrs), peak (24 hrs) and resolution 
(within 5 days). (E) Left. Levels of sCD86 measured in APAP-injury murine sera at 0 hrs, 8 
hrs, 24 hrs, 48hrs and 5 days post APAP-induced liver injury and Right corresponding ALT 
sera levels  (n=5 per group). 
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Figure 6. Plasma exchange results in the removal of circulating soluble CD80 and sCD86 
and the reduction of CTLA4 levels on CD4+ T cells. (A) Levels of soluble CD86 (Left panel) 
and sCD80 (middle panel) were assessed by ELISA in sera from pre and post PE patients and 
(B) in natural course samples. (A) Right CTLA4 levels were assessed by flow cytometry 
following cultures of purified CD4+ T cells from HCs in media supplemented with sera from 
pre and post PE patients (n=7) and (B) Right sera from natural course patients group who did 
not undergo PE (n= 7).  
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Supplementary Materials and Methods 
Collection of Peripheral Blood Mononuclear Cells (PBMCs), Isolation of CD4+ T Cells and 
Generation of Monocyte-Derived Dendritic Cells (DCs) 
PBMCs were isolated from whole blood through Ficoll-paque ™ Plus (GE Healthcare 
Bio-Sciences AB, Sweden) gradient centrifugation according to the manufacturer’s 
instructions. CD4+T cells and CD14+ monocytes were isolated by negative and positive 
magnetic bead selection, respectively (Miltenyi Biotec, Surrey, UK) according to the 
manufacturer’s instructions. Purified cells were routinely tested for purity using flow 
cytometry and were greater than 98%. Monocyte-derived DCs were generated from isolated 
CD14+ cells as previously described26.  Briefly, DCs were generated after 7 days of culture in 
the presence of recombinant human (rHu) IL-4 and granulocyte-macrophage colony-
stimulating factor (rHu GM-CSF) (eBioscience, Hatfield, UK).  DCs were characterized by 
the expression of CD1a, CD11c, HLA-DR, CD80, CD83, CD86, CD14. On day 6, DCs were 
matured by addition of Lipopolysaccharide (LPS) from Escherichia coli (E. coli) (1µg/ml) 
(Source BioScience, Nottingham, UK). DCs were cultured in RPMI medium supplemented 
with 10% fetal calf serum (FCS) and 2 mmol L-glutamine (Invitrogen, Paisley, UK). Viable-
cell counts were determined by trypan blue exclusion. 
Phenotyping Using Flow Cytometry 
PMBCs were surface stained for markers using the following pre-titrated 
fluorochrome-labelled mouse anti-human MAbs: CD3-eFluor®450, CD4-Brillaint violet 510, 
CD45RA-Brilliant violet 605, PD-1-Brilliant violet 786, CD45RO-FITC, CTLA4/CCR7-PE, 
CTLA4-PE, CD25 BD HorizonTM PE-CF594, CD62L PerCP-eFluor®710 (All from 
eBioscience, Hatfield, UK) and CD28/CD127 PE-Cy7, CD8/CD40L APC, (Becton 
Dickinson Ltd, Oxford, UK). Fluorescence minus one (FMO) controls for each marker were 
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used to set the gates to define the different subpopulations of lymphocytes. Cell Viability Dye 
eFluor®780 was used for the exclusion of dead cells. PBMCs were incubated in the presence 
of the antibodies or the corresponding FMO controls in the dark for 20 min (except for CCR7 
which was incubated for 45mnin) at 4°C. Single-color controls for compensation were 
performed using UltraComp eBeads (eBioscience, Hatfield, UK). The single stain 
compensation control for the cell viability dye eFluor®780 was performed using ArC beads 
(Thermo Fisher Scientific, Hemel Hempstead, UK) following the manufacture’s protocol. 
Twelve-color flow cytometric analyses were performed using Fortessa flow cytometer. Data 
were acquired using BD FACSDiva software (Becton Dickinson Ltd, Oxford, UK). A total of 
10,000-20,000 gated events were analyzed for each cell population. Data was analyzed using 
FlowLogic software (Inivai Technologies Pty Ltd, Victoria, Australia). When assessed for T 
cell proliferation using CPD dye eFluor®670 labelling, cells were labelled with CD3-
eFluor®450, CD4-Brillaint violet 510, CD8 APC, CD45RA-Brilliant violet 605 and 
CD45RO-FITC antibodies to assess proliferation of CD4+ T cells memory vs naïve 
populations.  
Primary Human Hepatocytes and Kupffer Cells (KC) 
Cryopreserved hepatocytes were obtained from Life technologies Ltd (Paisley, UK) 
and cultured following the manufacturer’s instructions. Hepatocytes were first thawed using 
Cryopreserved Hepatocyte Recovery Medium (CHRM), cell count and viability were 
determined using trypan blue staining. Viability was greater than 97%.  Cells were then 
plated using Cryopreserved Hepatocyte Plating Medium (CHPM) in 6 chamber slides 
collagen coated plates (Life technologies Ltd, Paisley, UK) at a lot-specific predetermined 
seeding density (0.9×106 cells /ml) for 4 hours to allow adherence of the cells before washing 
and replacing the CHPM with Williams’ E supplemented medium (Life technologies Ltd, 
Paisley, UK). Hepatocytes were allowed to further adhere overnight. Cultures were then 
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checked for their cell morphology and monolayer integrity under the microscope before being 
washed. Freshly supplemented media was replaced with medium only or medium containing 
20mM APAP (Sigma, Dorset, UK) for 24 hour exposure. Non-APAP controls were included.  
Cells were stained using apoptotic/necrotic cell kit (PromoCell GmbH, Heidelberg, Germany) 
Annexin V, Ethidium homodimer III (EthD-III), respectively and according to the 
manufacturer’s instructions.  Cells were then fixed in 4% paraformaldehyde and mounted 
using PromoFluor antifade Reagent (PromoCell GmbH, Heidelberg, Germany). Wide-field 
epi-fluorescence microscopy was performed on a Leica DMI6000B equipped with a 
Hamamatsu ORCA-ER CCD camera operated by the MetaMorph software (Molecular 
Devices). Cryopreserved KCs were obtained from Invitrogen and were recovered in DMEM 
thawing and plating media (Life technologies, Paisley, UK). KCs were seeded at a miminum 
density of 0.2-0.4×106 cells /ml on 24 well Cell bind plates (VWR, Lutterworth, UK). 
Following 3 hours of culture, the KCs were washed and media refreshed. Following 
overnight stimulation, media was replaced with DMEM maintenance media (Life 
technologies Ltd, Paisley, UK). KCs were then stimulated in the presence of LPS (1µg/ml) 
for 2 hours, washed then co-cultured with APAP treated hepatocytes at a 1:4 cell ratio 
overnight. Supernatants from hepatocyte and KC cultures were collected for assessment of 
soluble B7 using ELISA. 
Isolation and Culture of Human Biliary Epithelial Cells 
Human biliary epithelial cells (BECs) were isolated from 150g of human diseased 
liver tissue derived from acute liver failure (ALF, n=3) and chronic liver disease (CLD, n=6) 
patients. The liver tissue was enzymatically digested with collagenase type 1A (Sigma, UK), 
filtered and purified further via density gradient centrifugation over Percoll (Amersham 
Biosciences, UK). BECs were then extracted from the mixed non-parenchymal population 
via magnetic selection, as previously described27 and were cultured for one week (37˚C with 
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5% CO2) in rat-tail collagen coated flasks. After the first passage, BECs were cultured for 
24h and BEC culture supernatants were collected to soluble B7 using ELISA. 
Hepatic Endothelial Sinusoidal Cells (HSEC) Exposure to Plasma from ALF Patients  
48-well cell culture plate (Costar, Corning) were pre-coated with Type 1 rat-tail 
collagen (Sigma-Aldrich, UK). Human sinusoidal endothelial cells (HSEC) from an 
explanted liver with liver cirrhosis were cultured until confluent.  The cells were 
subsequently detached using cell-dissociating reagent TrypLE Express Enzyme (Gibco, Life 
Technologies, UK) for 5 minutes at 37°C, deactivated by addition PBS. A cell pellet was 
obtained by centrifugation at 2000rpm for 5 minutes. To each well was added 2×104 HSEC in 
a volume of 500µl of media (human endothelial serum free media (SFM), 10% human AB 
serum, recombinant vascular endothelial growth factor (VEGF) and hepatocyte growth factor 
(HGF) (PeproTech EC Ltd, London, UK) both at concentrations of 10ng/ml). Following 24-
hour incubation, cells were washed and cultured in SFM media supplemented with 2% fetal 
bovine serum (FBS) and recombinant VEGF and HGF at 10ng/ml (eBioscience, Hatfield, 
UK). After 24-hour culture, cells were washed and further incubated for 24 hours in the 
presence of sera from patients with ALF (n=6) or healthy controls (n=6) at 25%. Cells were 
further activated using 10ng/ml recombinant human tumour necrosis factor-α (TNF-α, 
PeproTech, UK) and 10ng/ml interferon-γ (IFNγ, PeproTech, UK). Supernatants were then 
collected and analysed for sB7 molecules.  
ELISA and MSD Multiplex Cytokine Detection System  
Soluble CD80 and CD86 were assessed in cell culture supernatants and human sera of 
(HC; n=4); and ALF (n=6); Sequential samples (D1, n=12; D3, n=6; D7, n=7; D14, n=5) 
using ELISA (eBioscience, Hatfield, UK and Cusabio, MD, USA respectively). In addition, 
Levels of sCD86 were quantified in sera from acetaminophen-induced (APAP) liver injury 
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model murine models using ELISA (Cusabio, MD, USA). Quantikine ELISA was used for 
IL-2 detection (R&D Systems, UK). The MSD Human TH1/TH2 10 plex panel was used to 
assess the following cytokines: IFN-γ, IL-1β, IL-2, IL-4, IL-8, IL-10, IL-12p70, IL-13 and 
TNF-α. ELISA microplates were read using the SoftMax® Pro software (Molecular Devices 
LLC, USA). MSD plates were acquired on the Sector Imager 2400 apparatus (Gaithersburg, 
MD). All ELISA and MSD experiments were performed in duplicate and according to the 
manufacturer's instruction. Total and caspase-cleaved cytokeratin 18 (M65 and M30, 
respectively) were measured in sera on admission in ALF (n=25), ACLF (n=20), CLD (n=15) 
and non-hepatic sepsis (n=20) using ELISA (Peviva AB, Bromma Sweden) and according to 
manufacturer’s instructions. Levels were assessed in supernatants from APAP untreated and 
treated primary human hepatocytes. 
Murine Sera Samples 
All research using live animals was approved by local ethics committees (Imperial 
College Central Animal Welfare Ethical Review Board (AWERB)) and was carried out under 
Home Office supervision in accordance with the Animal (Scientific Procedures) Act 1986 
(UK). Procedures were performed under the authority of UK project licence 70/7578. All 
efforts were taken to minimise animal suffering. Mice were housed in specific pathogen free 
conditions in individually ventilated cages (Techniplast UK Ltd). The environment was 
controlled with a 12 hour light/dark cycle, ambient temperature of 21°C (+/-2°C) and 
humidity of 55% (+/-10%). Mice had access to irradiated diet (Special Diet Services UK) and 
water (25ppm chlorine) ad libitum except when food was withdrawn for defined experimental 
purposes. Mice were fasted overnight for 12 hours, prior to intraperitoneal dosing with 
325mg/kg of APAP dissolved in saline by warming to 50°C for 45 minutes.  One 
experimental group were culled at baseline, following the overnight fast alone. Other groups 
of were culled at 8 hours, 24 hours, 48 hours and 5 days after dosing with APAP. At necropsy 
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the liver was excised; half was place in formalin for fixation and half was snap frozen in 
liquid nitrogen. Formalin fixed liver tissue was paraffin embedded, sectioned at 10µm 
thickness and mounted onto glass slides. Sections were stained with haematoxylin and eosin 
(H&E). 
Supplementary Figure Legends 
Supplementary Figure 1. Gating strategy to define lymphocyte subsets. (A) Representative 
dot plots of the gating strategy. Lymphocytes were first gated according to the forward and 
side scatter profile. Doublets were excluded from the analyses using side scatter area versus 
width discrimination. Dead cells, which were determined by positive staining for the cell 
viability dye, were then excluded. (B) CD3 then CD4 and CD8 markers were used to 
determine the lymphocyte primary populations which were then gated into subsets according 
to the corresponding fluorescence-minus-one (FMO) control (middle and bottom panels). 
SSC: side scatter, FCS-A: forward scatter area.  
Supplementary Figure 2. PBMCs were analysed for surface expression of co-stimulatory 
(CD28, C62L) and inhibitory molecules (PD1, CD25 and CD40L) in CD3+CD8-CD4+ T cells 
by flow cytometry (Healthy controls (HC), n=20; ALF, n=45; CLD; n=15, ACLF, n=20; non-
hepatic septic shock (sepsis), n=20).  
Supplementary Figure 3. Distribution of CTLA4+CD4+ in ACLF. (A) Longitudinal 
distribution of CTLA4 expression in sequential samples on days 1 (n=5), 3 (n=5), day 7 (n=4) 
and day 14 (n=5) following admission. (A) On day 1 of admission (n=15) and (B) CTLA4 
expression in culture-negative non-infected and culture-positive infected ACLF patients 
determined by flow cytometry. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplementary Figure 4. Distribution of CTLA4 surface expression in the 
CD127lowCD25high T regulatory cells. (A) on day 1 of admission (n=15) and (B) in 
longitudinal samples on days 1 (n=6), 3 (n=7), 7 (n=8) and 14 (n=5) following admission. 
Supplementary Figure 5. Distribution of CTLA4 surface expression in memory and naïve 
CD4+ T cell subsets in sequential samples of ALF patients who (A) developed infections and 
(B) the ones who did not develop infections. Left  panels Distribution of CTLA4 expression 
in memory CD4+ T cell subset. Right panels Distribution of CTLA4 expression in the naïve 
CD4+ T cell subset.  
Supplementary Figure 6. IFN-γ levels assessed by MSD. (A) Supernatants from cultures in 
the presence or absence of α-CTLA4 blocking antibody. (B) IFN-γ levels in cultures 
preconditioned in sera treated with α-CD80 and CD86 (right panel). (n=5). 
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Supplementary Table 1: Demographical and clinical parameters of acute liver failure (ALF), chronic liver 
disease (CLD), acute-on-chronic liver failure (ACLF), non-hepatic septic (sepsis) patients and healthy controls 
(HC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Values represent medians [interquartile range]. Abbreviations: SIRS score: Systemic Inflammatory 
Response Syndrome criteria score; MELD: Model for End stage Liver Disease; INR: international normalised 
ratio; AST: aspartate aminotransferase. NAFLD: non-alcoholic fatty liver disease; CVVH: Continuous Veno-
Venous Hemofiltration; OLT: orthotopic liver transplantation; NA: not applicable; ND: Not determined. 
#outcome at 28 days post admission. *P˂0.05, aSignificant differences comparing ALF to CLD patients, 
bcomparing ALF to ACLF and c comparing ALF to sepsis patients. #cause for decompensation in ACLF: 
alcoholic hepatitis (n=11), variceal bleed (n=2), sepsis (n=7). 
Parameter HC ALF CLD ACLF Septic 
Number of 
patients 
20 45 15 20 20 
Age, yr 
  
33.00 
[27.25-36.75] 
35.00*
abc
 
[26.50-48.5] 
59.00 
[44.5-61.60] 
51.70 
[39.00-61.50] 
48.00 
[32.25-61.25] 
Aetiology 
(number) 
NA Acetaminophen 
(35) 
Autoimmune (2) 
Seronegative (3) 
Drug induced liver 
injury (5) 
Alcoholic liver 
disease (13) 
HCV (1) 
Wilson’s disease 
(1) 
  
Alcohol related 
disease (16)# 
NAFLD (3)# 
Cryptogenic 
cirrhosis (1)# 
  
  
  
  
Pneumococcal (7) 
Urological (2) 
Streptococcal 
Cellulitis (3) 
Streptococcal 
meningitis (1) 
Liver abscess (1) 
Fournier’s (1) 
Chest sepsis (5) 
WBC 
(x109/L) 
NA 6.040*
a
 
[9.880-8.130] 
6.110 
 [4.000-5.200] 
8.100 
[4.300-13.55] 
9.335 
[5.528-13.52] 
Monocytes 
(x109/L) 
NA 0.2800*
a,b
 
[0.1300-0.5100] 
0.6000 
 [0.3000-0.4200] 
0.5750 
[0.4500-1.050] 
0.3350 
[0.1300-0.6850] 
Lymphocytes 
(x109/L) 
NA 0.6800*
a,b
 
[0.3300-1.190] 
1.400 
[0.700-1.770] 
0.6700 
[0.4525-1.350] 
0.6400 
 [0.275-0.9300] 
SIRS SCORE NA 3.000*
c
 
[2.000-4.000]  
ND 1.500 
[1.000-2.000] 
4.000 
[3.00-5.000] 
MELD score NA 38.00*
a,b
 
[31.00-40.00] 
11.00 
 [9.000-16.00] 
22.50 
[17.80-26.25] 
NA 
Child Pugh NA NA 8.000 
[6.000-9.000] 
10.00 
[9.000-13.00] 
NA 
SOFA score 
(CLIF SOFA 
score in ACLF) 
NA 13.50*
c
 
[7.750-17.00] 
NA 10.00 
[8.000-17.00] 
6.000 
[4.000-9.000] 
Bilirubin 
(µmol/L) 
NA 94.00*
a,b,c
 
[57.00-161.0] 
28.00 
[20.00-69.00] 
218.0 
[110.0-425.8] 
14.50 
[11.25-25.00] 
INR NA 3.840*
a,b,c
 
[2.450-6.295] 
1.300 
[1.200-1.440] 
1.655 
[1.475-1.950] 
1.430 
[1.190-1.918] 
Creatinine 
(µmol/L) 
NA 154.0*
a,b
 
[67.00-288.0] 
64.00 
[61.00-75.00] 
79.00 
[59.00-116.0] 
101.0 
[75.00-116.0] 
CVVH % (n) NA 60% (27) NA 45% (9) 40% (8) 
Urea 
(mmol/L) 
NA 7.200*
a
 
[5.300-13.10] 
4.300 
[3.100-5.350] 
5.500 
[4.050-7.325] 
5.850 
[3.600-8.100] 
AST 
(IU/ml) 
NA 3584*
a,b,c
 
[1010-6073] 
47.00 
[39.00-245.0] 
92.00 
[58.00-128.0] 
49.50 
[34.00-241.0] 
Ammonia 
(µmol/L) 
NA 94.00 
[65.00-127.0] 
89.00 
[88.00-90.00] 
ND ND 
Outcome
#
 
% (number) 
NA Spontaneous 
Survivors 69% (31) 
OLT 24.4% (11) 
 Non-survivors 
6.6% (3) 
 Survivors 100% 
(15) 
Spontaneous 
survivors 60% (12) 
OLT 15% (3) 
Non-survivors 25% 
(5) 
Survivors 95% (19) 
Non-survivors 5% 
(1) 
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Supplementary Table 2:  Demographical and clinical parameters of pre and post plasma exchanged 
acute liver patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Values represent medians [interquartile range]. Abbreviations: SIRS score: Systemic 
Inflammatory Response Syndrome criteria score; MELD: Model for End stage Liver Disease; INR: 
international normalised ratio; AST: aspartate aminotransferase. ALD: acute liver disease; OLT: 
orthotopic liver transplantation. 
 
 
Parameter Pre PE Post PE 
Number of patients 7 
Age, yr 46 
[36.5-52] 
Aetiology 
(number) 
Acetaminophen (5) 
Acute Wilson's disease (1) 
Liver trauma (1) 
WBC 
(×109/L) 
11.4 
[8.3-12.8] 
7.2 
[5.9-9.4] 
Monocytes 
(×109/L) 
0.1800 
[0.1100-0.3300] 
0.2400 
[0.1500-0.3000] 
Lymphocytes 
(×109/L) 
0.8 
[0.3-0.8] 
0.4 
[0.3-0.6] 
SIRS SCORE 2 
[2-3] 
2 
[2-3] 
MELD score 40 
[39-40] 
37 
[34-38] 
Bilirubin 
(µmol/L) 
87 
[73.5-97.5] 
95 
[88-112] 
INR 3.14 
[3.01-9.12] 
2.03 
[1.64-2.32] 
Creatinine 
(µmol/L) 
148 
[120-301] 
125 
[94.5-171] 
Urea 
(mmol/L) 
7.600 
[4.800-9.400] 
4.300 
[2.500-6.400] 
AST 
(IU/ml) 
5420 
[3424-8834] 
2196 
[1214-3587] 
Ammonia 
(µmol/L) 
58.00 
[39.50-71.50] 
45.00 
[14.00-201.0] 
Outcome OLT (2) 
Survivors (3) 
Non-survivors (2) 
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